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Abstract
Objectives: We investigated whether an intervention mainly consisting of a signed agreement between patient
and physician on the objectives to be reached, improves reaching these secondary prevention objectives in
modifiable cardiovascular risk factors six-months after discharge following an acute coronary syndrome.
Background: There is room to improve mid-term adherence to clinical guidelines’ recommendations in coronary
heart disease secondary prevention, specially non-pharmacological ones, often neglected.
Methods: In CAM-2, patients discharged after an acute coronary syndrome were randomly assigned to the
intervention or the usual care group. The primary outcome was reaching therapeutic objectives in various
secondary prevention variables: smoking, obesity, blood lipids, blood pressure control, exercise and taking of
medication.
Results: 1757 patients were recruited in 64 hospitals and 1510 (762 in the intervention and 748 in the control
group) attended the six-months follow-up visit. After adjustment for potentially important variables, there were,
between the intervention and control group, differences in the mean reduction of body mass index (0.5 vs. 0.2;
p < 0.001) and waist circumference (1.6 cm vs. 0.6 cm; p = 0.05), proportion of patients who exercise regularly and
those with total cholesterol below 175 mg/dl (64.7% vs. 56.5%; p = 0.001). The reported intake of medications was
high in both groups for all the drugs considered with no differences except for statins (98.1% vs. 95.9%; p = 0.029).
Conclusions: At least in the short term, lifestyle changes among coronary heart disease patients are achievable by
intensifying the responsibility of the patient himself by means of a simple and feasible intervention.
Background
Clinical practice guidelines recognise a series of pharma-
cological and hygienic-dietetic measures as being effec-
tive for secondary prevention in patients with acute
coronary syndrome [1]. However, in spite of the
improvement in recent years in measures to assure com-
pliance in secondary prevention in post-infarct patients,
there still exists considerable room for improvement
[2-9]. Adherence to the treatment recommended has a
favourable effect on the evolution of those patients who
comply. In patients with coronary heart disease, follow-
ing the recommendations of clinical guidelines in
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secondary prevention has a favourable effect on morbi-
mortality in the follow-up period [10-12]. Multiple stra-
tegies have been developed to improve the adherence of
patients to the recommendations, with more or less
impact on the achievement of aims [13,14]. But, on
occasion, these are focused exclusively on measures of
pharmacological prescription, and in others there is no
control group against which to assess the impact of the
measures adopted [15].
One last important aspect is the continuity of care
after hospital discharge. Measures in this respect have
been shown to be more effective the sooner they are
applied after the provision of care (such as when the
hospital discharge report itself is issued) [16]. Many
strategies to improve hospital care and recommenda-
tions at discharge are widely known, but rarely do they
attempt to go beyond the time of the actual submission
of the discharge report [17], even when the effectiveness
of carrying out early monitoring of patients discharged
after an acute coronary event is acknowledged [18].
The objective of our study is the evaluation after six
months of follow-up of a programme of intervention at
hospital discharge, easily embeddable in the daily clinical
practice, aimed at increasing the proportion of patients
that meet objectives in modifiable cardiovascular risk
factors among patients who suffered an acute coronary
syndrome, and which its main elements are the negotia-
tion between the patient and the physician on the
treatment objectives and steps to be taken and a reinfor-
cement visit two months after discharge.
Methods
Open-label randomized controlled trial performed with
64 Spanish hospitals participating, in which a maximum
of 30 patients were recruited at each one, all of whom
were discharged consecutively after suffering acute cor-
onary syndrome.
Finally, 1,757 patients were assigned to the Interven-
tion Group (n = 867) or the Control Group (n = 890)
by means of stratified randomization by centre and
with concealment of allocation sequence. The unit of
randomization was the patient and the stratification by
centre was done to remove the effect of the hospital
by obtaining groups of equal size (intervention and
control) in every hospital. These were not selected at
random but made up a convenient sample of Spanish
hospitals, many of which had already taken part in the
research group’s previous studies [16]. All participating
centers were either public or concerted with the public
system. The hospitals covered a wide range of size
(measured by the number of beds) and complexity. 16
hospitals had less than 400 beds, 22 between 400 and
800 and 26 hospitals had more than 800 beds. 39 hos-
pitals (61%) had cardiac catheterization laboratory.
There were hospitals from all over Spain, with sixteen
out of the seventeen autonomous communities of
Spain represented with at least one hospital as well as
thirtyfive out of the fifty provinces in which Spain is
divided.
The study was carried out during 2004 and 2006. The
study was approved by the Clinical Ethics and Research
Commission of Galicia (CEIC). All patients signed giving
their informed consent to participate in the trial.
Inclusion criteria
Patients of both genders admitted for acute coronary
syndrome with or without ST-segment elevation, dis-
charged with a diagnosis of Q-wave or non-Q-wave
acute myocardial infarction (AMI) or unstable angina
with sufficient cultural level to be able to understand
the intervention and the ability to fulfill the schedule of
proposed further visits (at two and six months). Patients
under 18 or above 80 years of age were not included, as
it was the case with those presenting accompanying ill-
nesses which would cause unfavourable prognosis in the
following months or which would prevent their partici-
pation. All patients received the usual information on
discharge.
Definition of the intervention
In this experimental study the intervention is realized
upon the physician/patient relationship. The interven-
tion includes a personalised interview at discharge with
patient and nearest next-of-kin, in which physician and
patient discuss and sign an agreement with the patient-
specific secondary prevention procedures and therapeu-
tic aims. Both physician and patient keep a copy of the
signed agreement. Written back-up information is also
given, some designed for this project and other based
on material available from the Spanish Society of Cardi-
ology, the Spanish Heart Foundation and the American
Heart Association ("After Your Heart Attack”, “Under-
standing and Controlling Your Cholesterol”, “The
Effects of Smoking”, “Warning Signs and Actions in the
Face of a Heart Attack” “Get Moving”, “Understanding
and Controlling Your Blood Pressure”, “Controlling
Your Weight”, among others) (materials available upon
request), as well as a phone number where to call in
case of questions.
The intervention also included an interview with the
patient two months after discharge in order to review
the agreement, adapt treatment if needed and reinforce
the intervention. Informative materials are given once
again.
Every visit (both at discharge and after two months)
took an average of 30-40 minutes each.
Patients assigned to the control group receive the
usual care given in each centre.
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Assessment of effects
The main outcome is the proportion of patients in each
therapeutic objective (Table 1). These objectives form
part of the intervention group’s physician/patient agree-
ment. There was direct measurement of blood pressure,
blood lipids and anthropometric variables. Medication
compliance, as well as smoking status and exercise were
self reported by the patient.
All data, both at baseline and follow-up, were col-
lected directly from the patients (or from hospital
records, in the case of biochemistry results) by the parti-
cipating physicians.
Plan of analysis
The comparison between intervention and control
groups regarding the proportion of patients who achieve
each one of the objectives (smoking, arterial hyperten-
sion (AHT), cholesterol, obesity) was done by means of
the chi-square test. The effect of intervention on vari-
ables indicated, adjusting for baseline differences (not
expected, taking into account the design chosen) which
might be confounding factors was done fitting a logistic
regression model for each objective (dependent variable:
achievement/non-achievement).
In order to compare average change (basal-final) in
continuous variables between intervention and control
groups, a model was adjusted by means of analysis of
variance (ANOVA) in which the dependent variable is
the change occurring between basal visit and final visit,
the main independent variable being whether they
belonged to the intervention or control groups, and
adjustment variables are those which display significant
baseline differences between control and intervention
groups, among patients who completed the follow-up
(analyses not presented): age group, level of education,
previous history of stroke, receiving medication for high
cholesterol and situation regarding the consumption of
tobacco prior to admission.
Subgroup analysis
In the protocol, pre-specified subgroup analyses by age
group (< 70 years of age and ≥70 years of age), gender,
and the existence or not of a personal history of
ischemic heart diseases were included. These are not
presented in this article.
Calculation of Sample Size
The original calculation was carried out for a minimum
of 40 participating centres and 1,200 patients recruited
(around half of them in each group). Assuming an
achievement rate of 50% in the control group (i.e. pro-
portion of patients in LDL objectives), this sample size
would give the study a power of 90% to detect differ-
ences of 10% in the achievement of objectives between
the two groups for an alpha error of 0.05.
Recruitment of centres was more successful than
anticipated and the large number of participating cen-
tres and patients recruited has enabled us to improve
our ability to detect differences between the groups. The
actual number of 1510 subjects improves the power to
Table 1 Objectives and indicators
Objectives Indicators
Giving up smoking % of patients who gave up smoking
% of patients who continued to smoke but reduced tobacco consumption
Having BMI < 25 % of patients with BMI ≥ 25 who reduced it by at least 10%
% of patients with BMI ≥ 25 who reduced it by at least 5%
% of patients who went from BMI ≥ 25 to BMI < 25
% of patients with BMI ≥ 30 who reduced it by at least 10%
% of patients with BMI ≥ 30 who reduced it by at least 5%
% of patients who went from BMI ≥ 30 to BMI < 30
Doing regular exercise % of patients who do physical exercise at least three times a week for at least 20/30 minutes
% of patients who do physical exercise at least five times a week for at least 20/30 minutes (only this exercise indicator
in diabetic patients)
Controlling lipid levels % of patients with total cholesterol < 175 mg/dl
% of patients with LDL cholesterol < 100 mg/dl (< 70 mg/dl in diabetics)
% of patients with LDL cholesterol < 70 mg/dl
% of patients with HDL cholesterol ≥ 40 mg/dl
% of patients with triglycerides < 150 mg/dl
Controlling hypertension % of patients with hypertension who have had their blood pressure controlled since discharge
% of patients with blood pressure < 135/80 mmHg (< 130/80 mmHg in diabetics)
Taking prescribed
medication
% of patients taking AAS (6 months) when prescribed at discharge
% of patients taking Clopidogrel (6 months) when prescribed at discharge
% of patients taking beta blockers (6 months) when prescribed at discharge
% of patients taking ACE-inhibitors (6 months) when prescribed at discharge
% of patients taking angiotensin receptor blocking agent Type II (ARA II) (6 months) when prescribed at discharge
% of patients taking statins (6 months) when prescribed at discharge
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detect the above mentioned difference to 97,5%. Conver-
sely, for a proportion of 50% in the control group and
an alfa error of 0.05, its actual sample size gives the
study a power of 90% to detect a minimum difference of
8.3% between the two groups.
Results
Baseline characteristics of the intervention and control
groups are displayed in Table 2. The randomization pro-
cess produced differences in a few potentially important
variables from the total number assessed. Summing up,
the intervention group had, on average, a slightly lower
age and a greater proportion of smokers at the onset of
the acute coronary syndrome, while the proportion of
diabetics was smaller. The visit at two months was effec-
tuated as planned by 726 of the 867 patients in the
intervention group (84%).
During the six-month follow-up period, 17 patients
died in the intervention group (2%) and 22 in the
control group (2.5%), a non-significant difference.
Another 88 patients from the intervention group and
120 from the control group failed to realize the fol-
low-up visit. This resulted in a difference in the pro-
portion of patients who completed the follow-up visit
(87,9% vs 84,0, p = 0,041), mainly due to “unknown
cause” (Figure 1).
The main results of the study are summarized in
Table 3, which presents the proportion of patients
achieving the various objectives defined and the degree
of improvement in the related quantitative variables.
It also presents the odds ratios of achieving different
objectives, adjusted for those variables which showed
differences between the two groups at the beginning of
the study (age group, educational level, previous history
of stroke, medication for cholesterol and tobacco con-
sumption prior to admission). As achieving treatment
objectives is something desirable, odds ratio above 1 are
good in this context. For continuous variables, instead
of adjusted odds ratios, the table presents adjusted dif-
ferences (for the same variables) in the mean changes
between the two groups.
To sum up, the tendency is always towards a greater
number of people achieving objectives within the inter-
vention group, but differences are only statistically sig-
nificant in the case of mean differences in body mass
index, waist measurement, patient’s own declaration of
exercise realized and total cholesterol level. With regard
to body mass index, even though the mean of this vari-
able is lower in the intervention group, the proportion
of patients achieving the predetermined objectives is
small, both among those who are overweight and those
who are obese, and there are no significant differences
between the intervention and control groups, even in
the case of the less ambitious objectives (reduction of at
least 5% of initial body mass index).
Discussion
This trial carries out a short-term assessment of a sim-
ple intervention in the relationship between physician
and patient in which its main element is the negotiation
Table 2 Comparison of Basal Characteristics of Intervention and Control Groups*
Intervention
(n = 867)
Control
(n = 890)
p-value
Males 77.7 75.6 0.301
Age (years old) (mean ± sd) 62.1 ± 11.6 63.6 ± 11.4 0.007
Present diagnosis AMI 65.9 64.6 0.304
Family history of ischemic cardiomyopathy 18.7 17.9 0.657
Certain previous diagnosis of ischemic cardiomyopathy 31.5 29.1 0.276
Personal history:
Stroke 4.8 6.4 0.156
Peripheral arteriopathy 8.8 9.3 0.683
Renal failure 5.3 5.8 0.624
Arterial hypertension 58.9 60.1 0.616
Hypercholesterolemia 51.4 50.7 0.748
Diabetes 25.3 29.6 0.044
Obesity 31.3 34.2 0.195
Smokers 33.3 26.1 0.001
BMI (kg/m2) (average ± sd) 28.2 ± 4.2 28.3 ± 4.3 0.627
BMI ≥ 30 kg/m2 29.6 30.4 0.932
Abdominal perimeter (men/women) ≥ 102/88 cm 47.8 51.8 0.172
Abdominal perimeter (men/women) ≥ 94/80 cm 74.0 74.3 0.929
* Results expressed as % unless otherwise indicated
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between the two and the ability to reach agreements
regarding which steps to take in relation to care and the
objectives to be fulfilled. The findings can be summed
up as a moderate but potentially important effect on
variables relating to lifestyle (physical exercise and body
mass index), which are usually the most difficult aspects
to modify. It also demonstrates that the vast majority of
patients state that they take the medication and that an
intervention such as that described above contributes
nothing in this respect, at least as far as we can judge
from the statements of the patients themselves, with all
the limitations that this implies.
Although many studies have attempted to improve
compliance levels in activities in secondary prevention
after an acute coronary syndrome, firstly, many of these
are focused exclusively on the moment of hospital dis-
charge, and secondly, the intervention takes place only
on the physician [14-17]. Thus, as a new element, our
study prolongs the time of the intervention beyond hos-
pital discharge, and moreover includes the patient as a
participant in the achievement of objectives. The agree-
ment signed by the patient, and early monitoring in the
clinic (two months after discharge) to reinforce the mes-
sage, were found to be related to a reduction in BMI, in
exercise carried out continuously and in the objective of
reaching levels of total cholesterol. These results suggest
that this type of interventions can result in an improve-
ment on the quality of care in this type of patients.
Intervention type and results
Early monitoring of coronary patients after discharge
subsequent to a coronary event has been related, in var-
ious studies, both with higher rates of pharmacological
compliance and with a favourable impact on patients’
evolution, with a reduction in hospitalizations and mor-
tality. Guidelines also recommend early monitoring
(2 to 6 weeks) even in low-risk patients, after an acute
coronary syndrome [19,20]. In our study, the interven-
tion performed is compared with common practice.
This is variable among centres, but common practice is
to refer a high proportion of patients to the general
practitioner on hospital discharge. In-depth interviews
between cardiologist and patient prior to discharge are
uncommon, due to the progressive reduction in time
spent in hospital by these patients. Our study, unlike
others, failed to demonstrate an improvement in levels
of pharmacological compliance. In part, this could be
explained by the absence of a control group in these
studies, so that the benefit reflected in these studies may
always be overrated. The positive effect of an early visit,
that took place after two months in our study, is related
to the fact that hospital discharge is usually a critical
moment where the change between hospital and out-
patient care (whether primary or specialized care) is a
period of vulnerability, when high rates of errors related
to medication and incomplete or inappropriate informa-
tion are present [21,22]. However, an early follow-up
visit can help prevent problems of primary compliance,
which in post-acute myocardial infarct patients can be
as high as 17.7% in cardiology medication [23].
Another tool used in our study is an agreement signed
by both physician and patient on the objectives to be
achieved during follow-up. This strategy is an attempt
to involve the patient as jointly responsible for his/her
care and avoid the relinquishment of his own function
within the health service which cares for him. This is
Figure 1 Flow-chart of follow-up of patients included in trial.
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justified by the fact that the patient’s collaboration and
responsibility are fundamental in aspects such as long-
term modification of lifestyle. Our study demonstrates
that this tool can be useful in achieving modifications in
lifestyle. However, though we consider that it is a key
element in the intervention, our study does not allow us
to evaluate the different components of the intervention
independently.
In our study we carried out an analysis, after 6 months,
of whether the intervention influenced patients’ self-
reported estimation of their pharmacological compli-
ance. We found no difference between the two groups
at six months except in the percentage of use of statins,
with a loss of only 1.9% in the intervention group, as
against 3.9% in the control group. The absence of this
effect could be explained by the short follow-up period
involved (6 months), especially because the time that
elapses since the acute event is recognized as a factor
contributing to non-compliance with treatment. Despite
a high self-reported adherence to the prescribed medica-
tion, there is still a low proportion of patients achieving
clinical goals. A similar observation has been reported
among coronary heart disease patients in a recent survey
in eight European countries [24], and in other studies
where achievement of lipid lowering goals may be as
low as 30% among high risk coronary heart disease
patients [25].
In summary, it is important to point out that the
improvements of the intervention concentrated in hygie-
nic-dietetic measures (regular practice of exercise and
weight loss and a non-significant tendency in the reduc-
tion in smoking) variables traditionally with lower com-
pliance and greater difficulties for improvement than
the pharmacological ones in other cardiovascular condi-
tions (i.e. heart failure) [26,27]. It is easier for a patient
to take medication than to change his lifestyle. Our
Table 3 Degree of Achievement of Objectives at Six Months in Both Groups
Objectives (nI/nC) Intervention
(n = 762)
Control
(n = 748)
Adjustedg
Odds ratio
Adjusted OR
95% CI
p-value
Given up smoking (253/200) 76.3 71.0 1.25 0.81-1.94 0.309
BMI ≥ 25 kg/m2 (567/547)
< 25 kg/m2 9.9 7.8 1.21 0.79-1.86 0. 373
⇓ BMI ≥ 10% 7.4 6.8 1.15 0.72-1.84 0.564
⇓ BMI ≥ 5% 25.0 19.7 1.31 0.98-1.76 0.068
BMI ≥ 30 kg/m2 (212/209)
< 30 kg/m2 25.9 24.9 1.04 0.66-1.63 0.860
⇓ BMI ≥ 10% 11.3 10.5 1.15 0.61-2.17 0.666
⇓ BMI ≥ 5% 32.1 27.8 1.26 0.82-1.93 0.300
Changes in BMI (average) (kg/m2)* - 0.5 - 0.2 0.35* 0.16-0.55* < 0.001
Changes in abdominal perimeter (average) (cm)* - 1.6 - 0.6 1.03* 0.00-2.06* 0.05
Exercise 5 times/week 29.4 23.4 1.29 1.02-1.64 0.033
Exercise 3 times/week 48.4 41.0 1.29 1.05-1.59 0.017
Cholesterol < 175 md/dl 64.7 56.5 1.46 1.17-1.81 0.001
LDL < 100 mg/dl (70 in diabetic patients) 47.9 44.8 1.09 0.87-1.35 0.449
BP < 135/80 mmHg (130/80 in diabetic patients) 46.7 42.4 1.14 0.91-1.41 0.253
Taking of medication (percentage who take it on final visit, out of total
given medication on discharge from hospital)
Aspirin (712/698) 97.5 96.0 1.54 0.84-2.83 0.161
Clopidogrel (571/533) 72.9 74.3 0.91 0.69-1.20 0.499
Beta-blockers (621/590) 94.4 94.6 0.93 0.56-1.54 0.769
ACE-inhibitors (400/387) 86.8 84.0 1.31 0.87-1.98 0.192
Angiotensin receptor blocking agent Type II (ARA II) (86/97) 84.9 86.6 0.83 0.35-1.95 0.664
Statins (677/635) 98.1 95.9 0.83 0.35-1.95 0.029
Results in intervention and control columns expressed as % of total number of patients affected by this objective as indicated in the first column, unless
otherwise indicated
g Differences in means (ANOVA model) or odds ratios [OR, logistic regression] adjusted for age group, education level, history of stroke, medication for
cholesterol and tobacco consumption prior to admission, variables with statistical significant differences at baseline in the group of patients included in this
analysis. Reference group for all estimates: control group). See interpretation of OR in the results section.
* In these continuous outcome variables, (changes in body mass index [BMI] and abdominal perimeter) the coefficients of the ANOVA model adjusted for the
same variables, instead of odds ratios, are presented.
nI/nC: Number of patients in intervention/control groups on which the percentages presented are based when they are not the same as the total indicated in
the corresponding column.
CI: Confidence interval
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study suggests that such changes are possible, at least in
the short term, by means of a simple and feasible inter-
vention that includes a component to increase the com-
promise from the patient (patient-physician agreement)
and a visit to reinforce the messages. Nevertheless, the
results also show that performance is still suboptimal,
and that there is a need of additional improvements.
Limitations
Compliance rates are typically higher among patients
with acute conditions compared with those suffering
from chronic pathologies, especially from 6 months on
[28,29]. This could be a limitation to the scope of our
study, given that it is a post-acute coronary syndrome
study and only covers monitoring up to 6 months. An
additional potential limitation is that physical activity is
declared by the patient him/herself, and there are no
mechanisms within the study that could make this more
objective. This is the usual practice in a clinical environ-
ment, but in this study poses the doubt that the differ-
ences might be due to a few patients with a contract
not wanting to admit breaking it. This does not seem to
be the reason because the patient-physician agreement
includes other self-reported variables besides lifestyle (i.e
medication adherence) where the effect is not seen.
On the other hand, it has been affirmed that colla-
borative follow-up protocols which actively involve pri-
mary care can be more effective than those performed
by one professional on his/her own involved in care of
the patient. The design of our study did not include
involvement of the primary care physician, a fact which
could limit the generalization of our results [30,31].
Conclusion
Taking medication is easier for a patient than changing
his/her lifestyle. As a conclusion and as possible sum-
mary message with clinical application, our study sug-
gests that, at least in the short term, lifestyle changes
are achievable by intensifying the responsibility of the
patient himself.
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